Jim Cramer says investors are too focused on AI stocks. Here’s where he says to look instead
CNBC’s Jim Cramer said Tuesday that investors need to expand their horizons beyond the artificial intelligence trade. “There’s…
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
Weight loss drug maker stock sinks 25% as safety data spooks investors
Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data…
FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
Biotech is resistant to AI disruption. Josh Brown likes these two stocks in the industry
(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo…
Eli Lilly’s lead in the obesity race gets wider after win against Novo
In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair…
Alphabet capex plans spook investors, while AMD has a brutal day in markets
Signage outside the Google headquarters in Mountain View, California, US, on Tuesday, Feb. 3, 2026. David Paul Morris…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…
I talked to many health CEOs out West and see big things for drug stocks
We get so caught up in the buzz and the sizzle that we forget about the steak, especially…
What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of…
What may be driving Eli Lilly shares lower — plus, oil, financial stocks rally
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Metsera Weight-Loss Drug Shows ‘Excellent’ Tolerability in Study
Metsera Inc.’s next-generation weight-loss drug showed good tolerability with few participants dropping out of a mid-stage trial, adding…